PAVELEK, Zbyšek, Oldřich VYŠATA, Vojtěch TAMBOR, Kristýna PIMKOVÁ, Dai Long VU, Kamil KUČA, Pavel ŠTOURAČ and Martin VALIŠ. Proteomic analysis of cerebrospinal fluid for relapsing-remitting multiple sclerosis and clinically isolated syndrome. Biomedical Reports. Athens: Spandidos Publications, 2016, vol. 5, No 1, p. 35-40. ISSN 2049-9434. Available from: https://dx.doi.org/10.3892/br.2016.668.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Proteomic analysis of cerebrospinal fluid for relapsing-remitting multiple sclerosis and clinically isolated syndrome
Authors PAVELEK, Zbyšek (203 Czech Republic), Oldřich VYŠATA (203 Czech Republic), Vojtěch TAMBOR (203 Czech Republic), Kristýna PIMKOVÁ (203 Czech Republic), Dai Long VU (203 Czech Republic), Kamil KUČA (203 Czech Republic), Pavel ŠTOURAČ (203 Czech Republic, guarantor, belonging to the institution) and Martin VALIŠ (203 Czech Republic).
Edition Biomedical Reports, Athens, Spandidos Publications, 2016, 2049-9434.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30000 3. Medical and Health Sciences
Country of publisher Greece
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/16:00093167
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3892/br.2016.668
UT WoS 000379957300007
Keywords in English multiple sclerosis; clinically isolated syndrome; cerebrospinal fluid; proteomic analysis; biomarkers; proteins
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 25/1/2017 12:12.
Abstract
Early diagnosis and treatment of multiple sclerosis (MS) in the initial stages of the disease can significantly retard its progression. The aim of the present study was to identify changes in the cerebrospinal fluid proteome in patients with relapsing-remitting MS and clinically isolated MS syndrome who are at high risk of developing MS (case group) compared to healthy population (control) in order to identify potential new markers, which could ultimately aid in early diagnosis of MS. The protein concentrations of each of the 11 case and 15 control samples were determined using a bicinchoninic acid assay. Nanoscale liquid chromatography coupled with tandem mass spectrometry was used for protein identification. Proteomics data were processed using the Perseus software suite and R. The results were filtered using the Benjamini-Hochberg procedure for the false discovery rate (FDR) correction (FDR<0.05). The results showed that, 26 proteins were significantly dysregulated in case samples compared to the controls. Nine proteins were found to be significantly less abundant in case samples, while the abundance of 17 proteins was significantly increased in case samples compared to controls. Three of the proteins were previously linked to RR MS, including immunoglobulin (Ig) gamma-1 chain C region, Ig heavy chain V-III region BRO and Ig kappa chain C region. Three proteins that were uniquely expressed in patients with RR MS were identified and these proteins may serve as prognostic biomarkers for identifying patients with a high risk of developing RR MS.
PrintDisplayed: 24/8/2024 19:33